Evidence map›Paper›PMID 40464559›Full record

ArticlemBio2025

Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in

Bartosz J Bartmanski, Anja Bösch, Steven Schmitt, Niranjan R Ireddy, Qun Ren, Jacqueline Findlay, Adrian Egli, Maria Zimmermann-Kogadeeva, Baharak Babouee Flury

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bartosz J Bartmanski *Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.ORCID 0000-0002-0495-9150
Anja Bösch *HOCH, Cantonal Hospital St. Gallen, Medical Research Center, St. Gallen, Switzerland.
Steven SchmittDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.
Niranjan R IreddyHOCH, Cantonal Hospital St. Gallen, Medical Research Center, St. Gallen, Switzerland.
Qun RenEmpa, Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland.ORCID 0000-0003-0627-761X
Jacqueline FindlayMedical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.ORCID 0000-0002-7335-9001
Adrian EgliInstitute of Medical Microbiology, University of Zürich, Zürich, Switzerland.ORCID 0000-0002-3564-8603
Maria Zimmermann-KogadeevaGenome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.ORCID 0000-0001-6021-1246
Baharak Babouee FluryHOCH, Cantonal Hospital St. Gallen, Medical Research Center, St. Gallen, Switzerland.ORCID 0000-0001-8966-5882

Funding

European Molecular Biology LaboratoryResearch Committee of Cantonal Hospital St. Gallen
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDrug Resistance, Multiple, BacterialMeropenemPseudomonas aeruginosaBacterial ProteinsDrug CombinationsHumansMicrobial Sensitivity TestsMultiomicsProteomicsPseudomonas InfectionsWhole Genome SequencingAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial ProteinsCeftazidimeDrug CombinationsMeropenemceftazidime-avibactamCRISPR/Cas9dacBgenomicsmachine learningmeropenemproteomicsPseudomonas aeruginosaresistance mechanismstranscriptomics

Identifiers

PMID40464559
PMCPMC12239554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.